Brief: Cabaletta Bio Announces FDA Granted Orphan Drug Designation To CABA-201 For Treatment Of Myositis
01/02/2024 22:30
Feb 1 (Reuters) - Cabaletta Bio Inc CABA.O :
* CABALETTA BIO ANNOUNCES FDA GRANTED ORPHAN DRUG
DESIGNATION TO
CABA-201 FOR TREATMENT OF MYOSITIS
Source text for Eikon: ID:nGNX4GjffH
Further company coverage: CABA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity